The class B shares of BioGaia AB are listed on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. See share information from OMX Nasdaq Stockholm. Read more


Financial interviews

Interview with CEO Axel Sjöblad, Q4 2017

 Archive with older interviews and presentations


Investors contact

Margareta Hagman, CFO

Phone:+46 (0)8 555 293 04
Mobile:+46 (0)708 72 82 33


Analysts covering BioGaia

Carnegie, Kristofer Liljeberg
SEB, Richard Koch



Investor presentation


BioGaia Annual report



Read more

About BioGaia

BioGaia is an innovative Swedish health care company and a world leader in probiotics with more than 25 years experience of developing, marketing and selling probiotic products.

Read more


We have a clear strategy and have set the goals and priorities for 2018. Our sustainability initiatives have been given structure and a long-term approach.

Read more

Clinical studies

To date, 184 clinical studies using BioGaia’s human strains of Lactobacillus reuteri have been performed on 15,500 individuals of all ages (February 2018).

Read more